Roche's Spark Therapeutics, NeuExcell Join Forces To Develop Huntington's Disease Gene Therapy

by Vandana Singh, Benzinga Editor

September 7, 2021 6:55 AM | 1 min read |

Privately-held NeuExcell Therapeutics has collaborated with Spark Therapeutics to develop a treatment for Huntington's Disease (HD).
Spark Therapeutics is a part of Roche Holdings AG RHHBY.
Under the deal, Spark Therapeutics has the option to license the exclusive worldwide rights of NeuExcell's HD program.
Under the Option, NeuExcell said it is eligible to receive upfront, license fees, R&D, and sales milestone payments up to about $190 million, plus product royalties.
Under terms, Spark Therapeutics will get access to NeuExcell's proprietary neuro-regenerative gene therapy platform and capabilities.
NeuExcell's research team will collaborate closely with Spark Therapeutics to advance the program.
Price Action: RHHBY shares closed at $49.75 on Friday.

Posted In: Biotech News Health Care Contracts General Briefs gene therapy Huntington's Disease

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.